Article
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Nature communications - 17 Jun 2021
Poels Kamrine E, Schoenfeld Adam J, Makhnin Alex, Tobi Yosef, Wang Yuli, Frisco-Cabanos Heidie, Chakrabarti Shaon, Shi Manli, Napoli Chelsi, McDonald Thomas O, Tan Weiwei, Hata Aaron, Weinrich Scott L, Yu Helena A, Michor Franziska
Abstract excerpt
Despite the clinical success of the third-generation EGFR inhibitor osimertinib as a first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC), resistance arises due to the acquisition of EGFR second-site mutations and other mechanisms, which necessitates alternative therapies. Dacomitinib, a pan-HER inhibitor, is approved for first-line treatment and results in different acquired EGFR mutations than...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.